HK Innoen Demonstrates Safety and Efficacy in Patients with Acute Myocardial Infarction

On September 10, HK Innoen announced the results of a study comparing the safety of the new gastroesophageal reflux disease drug K-CAB (active ingredient: tegoprazan) with that of the PPI class in the treatment of cardiovascular patients.

Professor Oh Hyun Lee of the Cardiology Department at Yongin Severance Hospital is presenting the research results of K-CAB at the European Society of Cardiology. HK Innoen

This study, led by a research team from Yongin Severance Hospital at Yonsei University College of Medicine, focused on patients with acute myocardial infarction who were treated with dual antiplatelet therapy (DAPT) after undergoing percutaneous coronary intervention (PCI).

Dual antiplatelet therapy (DAPT) is a treatment that reduces ischemic events after percutaneous coronary intervention (PCI) in patients with cardiovascular disease, but it is known to increase the risk of gastrointestinal bleeding.

Although PPI class drugs are widely used to prevent gastrointestinal bleeding, concerns about drug interactions with antiplatelet agents have been continuously raised.

The research team focused on K-CAB, a P-CAB class drug with characteristics such as rapid onset of action, long duration, and low drug interaction, and conducted this study to assess its potential as a replacement for PPI class products.

The researchers utilized nationwide big data from the Health Insurance Review and Assessment Service to compare and analyze patients with acute myocardial infarction (AMI) who underwent percutaneous coronary intervention (PCI) in Korea and were treated with dual antiplatelet therapy (DAPT) along with either PPI class drugs (19,201 patients) or tegoprazan (2,075 patients).

After statistically adjusting for baseline characteristics between the two patient groups, the research team set major endpoints as gastrointestinal bleeding, myocardial infarction, and major adverse cardiac and cerebrovascular events (MACCE), including stroke, within one year.

The results showed that the group taking K-CAB had about a 28% lower risk of gastrointestinal bleeding within one year compared to the PPI group, and it was confirmed that the risk of major adverse cardiac and cerebrovascular events, such as myocardial infarction or stroke, did not increase.

Kim Yongcheol, Professor of Cardiology at Yongin Severance Hospital, who led the study, stated, "We have confirmed that K-CAB can be an effective and safe gastroprotective drug compared to conventional PPIs for East Asian myocardial infarction patients receiving dual antiplatelet therapy (DAPT)."

Lee Ohyun, Professor of Cardiology at Yongin Severance Hospital, said, "As we enter a super-aged society, the number of cardiovascular disease patients is increasing, and consequently, so is the mortality rate. In particular, managing gastrointestinal bleeding during dual antiplatelet therapy (DAPT) after procedures is crucial, and these study results demonstrate that K-CAB can be a safe and effective alternative."

A representative from HK Innoen commented, "Through these study results, we expect that K-CAB can provide differentiated clinical value in the treatment environment for cardiovascular patients."